Online Trial Tracker - Larvol Sigma

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Torisel (temsirolimus) / Pfizer

TAPUR, NCT02693535: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Recruiting

3791

Palbociclib, Ibrance, Sunitinib, Sutent, Temsirolimus, Torisel, Trastuzumab and Pertuzumab, Herceptin and Perjeta, Vemurafenib and Cobimetinib, Zelboraf and Cotellic, Regorafenib, Stivarga, Olaparib, Lynparza, Pembrolizumab, Keytruda, Nivolumab and Ipilimumab, Opdivo and Yervoy, Abemaciclib, Verzenio, Talazoparib, Talzenna, Atezolizumab and PHESGO, Tecentriq and PHESGO, Atezolizumab and Talazoparib, Tecentriq and Talzenna, Entrectinib, Rozlytrek, Larotrectinib, Vitrakvi, Tucatinib plus Trastuzumab Subcutaneous (SC), Tukysa and Herceptin Hylecta, Futibatinib, Lytgobi

American Society of Clinical Oncology, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme LLC, Pfizer, Boehringer Ingelheim, Seagen Inc., Taiho Oncology, Inc.

Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors

12/24

12/25

CAPTUR, NCT03297606: Canadian Profiling and Targeted Agent Utilization Trial

Recruiting

720

Canada

Olaparib, Dasatinib, Nivolumab plus Ipilimumab, Axitinib, Bosutinib, Crizotinib, Palbociclib, Sunitinib, Temsirolimus, Erlotinib, Trastuzumab plus Pertuzumab, Vemurafenib plus Cobimetinib, Vismodegib, Tucatinib

Canadian Cancer Trials Group, AstraZeneca, Bristol-Myers Squibb, Hoffmann-La Roche, Pfizer, Seagen Inc.

Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors

01/26

01/27

NCT05406154: Ibrutinib Combined With Bendamustine and Rituximab in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged > 65 Years

Recruiting

N/A

RoW

Peking University Third Hospital, Peking Union Medical College Hospital, The Second Affiliated Hospital of Dalian Medical University, Peking University First Hospital, Beijing Tongren Hospital, Beijing Hospital, Beijing Tsinghua Changgeng Hospital, China-Japan Friendship Hospital, 307 Hospital of PLA, Chinese PLA General Hospital, First Affiliated Hospital of Harbin Medical University, Harbin Medical University, Baotou Cancer Hospital, Beijing Shijitan Hospital, Capital Medical University, Shanxi Province Cancer Hospital, Beijing Naval General Hospital, First Hospital of China Medical University, Jilin Provincial Tumor Hospital, Shengjing Hospital

Mantle Cell Lymphoma (MCL)

12/23

07/24

NCT05429918: Ibrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged ≤65 Years

Recruiting

N/A

RoW

Peking University Third Hospital, The Second Affiliated Hospital of Dalian Medical University, Peking University First Hospital, Beijing Hospital, Beijing Tsinghua Changgeng Hospital, China-Japan Friendship Hospital, Chinese PLA General Hospital, First Affiliated Hospital of Harbin Medical University, Baotou Cancer Hospital, Beijing Shijitan Hospital, Capital Medical University, Shanxi Province Cancer Hospital, Beijing Naval General Hospital, First Hospital of China Medical University, Jilin Provincial Tumor Hospital, Shengjing Hospital, 307 Hospital of PLA, Peking Union Medical College Hospital, Harbin Medical University, Beijing Tongren Hospital

Mantle Cell Lymphoma

12/23

06/24



	Diseases Companies Products Productz Mechanisms of Action Sites